Indication

Hemoglobin H disease

Hemoglobin H disease is a moderate-to-severe form of alpha-thalassemia, a genetic hematologic disorder caused by the loss or inactivation of three of the four functional alpha-globin genes. Read more about Hemoglobin H disease

1 drugs 1 manufacturers

Advertisement

Drugs that treat it

Common Hemoglobin H disease therapies.

Showing 1–1 of 1 drugs

Filter & compare in the drug finder →Opens the drug finder with Hemoglobin H disease preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Hemoglobin H disease.

Hemoglobin H disease is a moderate-to-severe form of alpha-thalassemia, a genetic hematologic disorder caused by the loss or inactivation of three of the four functional alpha-globin genes.

This deficiency produces an imbalance between alpha- and beta-globin chains, resulting in the assembly of unstable beta-globin tetramers known as hemoglobin H within erythrocytes.

The condition primarily impacts the hematologic and reticuloendothelial systems, leading to chronic microcytic hypochromic hemolytic anemia, ineffective erythropoiesis, splenomegaly, and jaundice.

Clinical manifestations range from mild thalassemia intermedia to severe anemia with complications such as cholelithiasis, acute hemolytic crises triggered by infections or oxidant stress, and secondary iron overload.

Personalize your experience

Follow Hemoglobin H disease and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it